Breaking News Instant updates and real-time market news.

FB

Facebook

$195.02

12.38 (6.78%)

, AXP

American Express

$115.47

1.45 (1.27%)

10:16
04/25/19
04/25
10:16
04/25/19
10:16

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at UBS with analyst Eric Sheridan saying while 2019 remains a year of transition, Facebook management has now produced multiple quarters of better than expected revenue and earnings. 2. American Express (AXP) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Betsy Graseck saying she believes its strong revenue growth remains intact given its record growth in proprietary cards, strong contribution from Millennials, fee-based products and its strong loan and transactional growth. 3. Novartis (NVS) upgraded to Buy from Neutral at Guggenheim with analyst Seamus Fernandez saying he is more confident that the company "can deliver several years of mid-single digit operating profit and EPS growth" through 2024. 4. Sirius XM (SIRI) upgraded to Buy from Hold at Pivotal Research with analyst Jeffrey Wlodarczak saying yesterday's post-earnings selloff was overdone as investors overreacted to slightly lower than expected new car installations and modestly lower than expected self-pay net subscriber additions. 5. General Dynamics (GD) upgraded to Neutral from Underweight at JPMorgan with analyst Seth Seifman saying General Dynamics has underperformed the market by~21% since the start of 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

FB

Facebook

$195.02

12.38 (6.78%)

AXP

American Express

$115.47

1.45 (1.27%)

NVS

Novartis

$79.79

2 (2.57%)

SIRI

Sirius XM

$5.75

0.035 (0.61%)

GD

General Dynamics

$176.30

-4.37 (-2.42%)

  • 28

    Apr

  • 28

    Apr

  • 01

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 14

    May

  • 17

    May

  • 18

    May

  • 23

    May

  • 23

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 13

    Nov

FB Facebook
$195.02

12.38 (6.78%)

04/25/19
FBCO
04/25/19
NO CHANGE
Target $235
FBCO
Outperform
Facebook price target raised to $235 from $211 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Facebook to $235 from $211 saying that after a year of controversy, he welcomes a straightforward quarter, as ad revenue grew 31%-plus on an FX Neutral basis driven by ongoing pricing and monetization strength on both core Facebook and Instagram. The analyst reiterates an Outperform rating on the shares.
04/25/19
BMOC
04/25/19
NO CHANGE
Target $200
BMOC
Market Perform
Facebook price target raised to $200 from $190 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Facebook to $200 and also raised his FY19 EPS view to $7.76 from $7.41 after its better than expected Q1 results, noting that the management reduced its outlook for operating expense in 2019. The analyst is keeping his Market Perform rating on Facebook shares however, forecasting the company's revenue deceleration to bottom in Q4 of this year before an upward inflection in Q1 on ramping Stories demand. Salmon adds that despite the "regulatory overhang", he remains on the "positive side" of his rating as the stock price has reflected his "more cautious view on margins".
04/25/19
COWN
04/25/19
NO CHANGE
Target $225
COWN
Outperform
Facebook price target raised to $225 from $195 at Cowen
Cowen analyst John Blackledge raised his price target for Facebook to $225 from $195 after the company reported "strong" Q1 results. The analyst reiterates an Outperform rating on the shares.
04/25/19
RBCM
04/25/19
NO CHANGE
Target $250
RBCM
Outperform
Facebook price target raised to $250 from $200 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Facebook to $250 and kept his Outperform rating after its Q1 revenue and operating income topped expectations on the strength of its Instagram performance and the pricing power of its advertising platform. The analyst notes that the quarter has made him "more positive" at the margin with the company's worst fears "not realized" and adding that the stock may be in a period of a "sustained re-rating."
AXP American Express
$115.47

1.45 (1.27%)

04/02/19
SPHN
04/02/19
NO CHANGE
Target $63
SPHN
Overweight
Airlines needed some good news, and Delta delivered, says Stephens
With investor sentiment on the airline space negative, the group was in need of some good news and Delta Air Lines delivered a positive surprise this morning, Stephens analyst Jack Atkins tells investors in a research note. The airline pointed Q1 RASM growth to the upper-end of its initial guidance range, lowered its Q1 CASM excluding fuel expectation and raised its Q1 earnings guidance range, says the analyst. Atkins finds it encouraging that Delta noted underlying passenger demand remains solid and that the business market led the way during the quarter. Further, the company announced an extension of its credit card partnership with American Express (AXP), which is expected to double the revenue contribution to $7B by 2023 versus 2018 levels, he notes. Atkins reiterates an Overweight rating on Delta with a $63 price target. The stock in midday trading is up 7% to $55.64. Other names in the airline space include Alaska Air (ALK), American Airlines (AAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Continental (UAL).
04/03/19
STFL
04/03/19
NO CHANGE
Target $85
STFL
Buy
Delta Air Lines price target raised to $85 from $80 at Stifel
Stifel analyst Joseph DeNardi raised his Q1 and 2019 EPS estimates for Delta (DAL) to reflect the company's revised Q1 guidance and increased his price target on the stock to $85 accordingly. Based on the company's comments on its new card deal with American Express (AXP), DeNardi believes Delta's economics from the pact improved by about 10% versus their prior agreement. He maintains a Buy rating on Delta shares.
04/25/19
MSCO
04/25/19
UPGRADE
MSCO
Overweight
American Express upgraded to Overweight from Equal Weight at Morgan Stanley
04/25/19
MSCO
04/25/19
UPGRADE
Target $140
MSCO
Overweight
American Express upgraded to Overweight on sustainable growth at Morgan Stanley
As previously reported, Morgan Stanley analyst Betsy Graseck upgraded American Express to Overweight from Equal Weight, stating that she believes its strong revenue growth remains intact given its record growth in proprietary cards, strong contribution from Millennials, fee-based products and its strong loan and transactional growth. The analyst, who expects revenue growth to rebound from 7% in Q1 to 8%-10% starting in Q2, raised her 2020 EPS estimate by 6% and increased her price target on AmEx shares to $140 from $123.
NVS Novartis
$79.79

2 (2.57%)

04/24/19
GUGG
04/24/19
UPGRADE
GUGG
Buy
Novartis upgraded to Buy from Neutral at Guggenheim
04/25/19
04/25/19
UPGRADE

Buy
Novartis upgraded to Buy from Neutral at Guggenheim
As previously reported, Guggenheim analyst Seamus Fernandez upgraded Novartis to Buy with a price target of CHF95, saying he is more confient that the company "can deliver several years of mid-single digit operating profit and EPS growth" through 2024. The analyst notes that investors have an "attractive opportunity" given the company's "structural shift in operating margins driven by transformational SMA gene therapy, Zolgensma, a best-case Mayzent label in MS, and several near-term pipeline catalysts."
04/24/19
WELS
04/24/19
NO CHANGE
WELS
Sandoz results should not be seen as positive for generics, says Wells Fargo
Wells Fargo analyst David Maris sees nothing in the Q1 results from Novartis (NVS) unit Sandoz that points to a dramatically improving U.S. generic pricing environment. We would tot read the Sandoz results as a positive for generic companies such as Teva (TEVA) and Mylan (MYL), and commentary about generic Copxone pricing trends is a negative, Maris tells investors in a research note. He believes Sandoz trends are important to watch as a potential read-through for other generic drug company results. Novartis continues to see higher generic headwinds in the remainder of 2019, Maris points out, citing comments from the earnings call.
04/17/19
JEFF
04/17/19
NO CHANGE
Target $343
JEFF
Hold
Regeneron price target lowered to $343 from $376 at Jefferies
Jefferies analyst Biren Amin lowered his price target for Regeneron Pharmaceuticals (REGN) to $343 from $376 after doctors in his firm's survey viewed Novartis' (NVS) brolucizumab favorably. Retina specialists are particularly eager to prescribe brolucizumab, Amin tells investors in a research note. "Conservatively" incorporating the doctor estimates for brolucizumab uptake cuts revenue for Regeneron's Eylea in wet age-related macular degeneration by 13% over next two years, says the analyst. His revised Eylea estimates are now 4%-7% below consensus for fiscal 2020 through 2023. Amin thinks the Street underestimates the impact of the brolucizumab entry, which he thinks could "replicate events seen when Eylea launched and encroached on Lucentis share." The analyst keeps a Hold rating on Regeneron.
SIRI Sirius XM
$5.75

0.035 (0.61%)

01/30/19
01/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. United Continental (UAL) initiated with a Buy at Argus. 2. Amicus (FOLD) initiated with an Overweight at Cantor Fitzgerald. 3. Take-Two (TTWO) and Zynga (ZNGA) were initiated with a Buy at Goldman Sachs, while Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Neutral. 4. Sirius XM (SIRI) resumed with a Buy at B. Riley. 5. National Grid (NGG) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/19
PIVT
04/25/19
UPGRADE
Target $7
PIVT
Buy
Sirius XM upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Jeffrey Wlodarczak upgraded Sirius XM Radio to Buy from Hold with an unchanged price target of $7. Yesterday's post-earnings selloff was overdone as investors overreacted to slightly lower than expected new car installations and modestly lower than expected self-pay net subscriber additions, Wlodarczak tells investors in a research note. He believes Sirius is already demonstrating an ability to "significantly" increase monetization of Pandora's "still sizeable" free streaming subscriber base.
01/29/19
RILY
01/29/19
INITIATION
Target $8
RILY
Buy
Sirius XM resumed with a Buy at B. Riley
B. Riley resumed Sirius XM with a Buy rating and a price target of $8.
03/15/19
MSCO
03/15/19
INITIATION
Target $6.5
MSCO
Equal Weight
Sirius XM resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne resumed coverage of Sirius XM (SIRI) with an Equal Weight rating and $6.50 price target, noting that acquiring Pandora with shares was dilutive to free cash flow per share but something he considers "a relatively low risk bet." He expects pro forma SiriusXM to grow revenue and adjusted EBITDA at a 6% and 9% 5-year CAGR respectively from 2019-2023. Swinburne also resumed coverage of Liberty Sirius XM (LSXMK) with an Overweight rating.
GD General Dynamics
$176.30

-4.37 (-2.42%)

04/25/19
JPMS
04/25/19
UPGRADE
Target $200
JPMS
Neutral
JPMorgan upgrades General Dynamics to Neutral, sees fair valuation
JPMorgan analyst Seth Seifman upgraded General Dynamics to Neutral from Underweight and raised his price target for the shares to $200 from $188. General Dynamics has underperformed the market by~21% since the start of 2018, Seifman tells investors in a research note. The analyst now sees a "reasonable valuation" and and "fewer obstacles ahead" for the company. He thinks the long-term challenges to Aero profitability from lower G650 production and new competition are well understood at current share levels.
04/25/19
JPMS
04/25/19
UPGRADE
Target $200
JPMS
Neutral
General Dynamics upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Seth Seifman upgraded General Dynamics to Neutral from Underweight and raised his price target for the shares to $200 from $188.
02/15/19
02/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) downgraded to Neutral from Buy at Citi with analyst Wendy Nicholson saying the company's guidance implies 2019 earnings growth of plus or minus 1%. Coca-Cola has reported earnings per share of $2.00, plus or minus 10c, for the last eight years, with strong underlying growth offset by dilution from refranchising activities and currency headwinds. 2. General Dynamics (GD) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Springarn saying the acquisition of CSRA appears to be only "nominally accretive" to 2019, well short of his expectations, and says he believes the acquisition has significantly reduced the company's balance sheet flexibility and may limit future shareholder returns. 3. Ball Corp. (BLL) downgraded to Neutral from Buy at UBS with analyst Edlain Rodriguez saying while Ball's fundamentals "remain solid," a higher multiple "is a stretch" with the stock already up 45% over the past year. 4. Six Flags (SIX) downgraded to Sector Weight from Overweight at KeyBanc with analyst Brett Andress saying he remains constructive on the broader theme park industry and the majority of Six Flags' growth pillars, but international upside had been a key component of his thesis and the significantly reduced visibility and potential downside prompts the downgrade. 5. LogMeln (LOGM) downgraded to Perform from Outperform at Oppenheimer and to Hold from Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
02/15/19
FBCO
02/15/19
DOWNGRADE
Target $184
FBCO
Neutral
General Dynamics downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Robert Springarn downgraded General Dynamics to Neutral from Outperform and lowered his price target to $184 from $190. In a research note to investors, Springarn says the acquisition of CSRA appears to be only "nominally accretive" to 2019, well short of his expectations, and says he believes the acquisition has significantly reduced the company's balance sheet flexibility and may limit future shareholder returns. Additionally, Springarn sees increasing competitive threats in both IT and Aerospace, which dims his growth outlook. Springarn says he is no longer convinced that General Dynamics can outperform, at least until management can show that its strategy warrants a higher multiple.

TODAY'S FREE FLY STORIES

UNH

UnitedHealth

$247.78

-2.47 (-0.99%)

19:29
06/20/19
06/20
19:29
06/20/19
19:29
Periodicals
UnitedHealth to acquire Equian from New Mountain Capital, WSJ says »

UnitedHealth has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 18

    Jul

KFY

Korn/Ferry

$48.61

1.04 (2.19%)

, EXEL

Exelixis

$21.14

0.15 (0.71%)

19:05
06/20/19
06/20
19:05
06/20/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

KFY

Korn/Ferry

$48.61

1.04 (2.19%)

EXEL

Exelixis

$21.14

0.15 (0.71%)

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

PYPL

PayPal

$118.82

1.66 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

EXEL

Exelixis

$21.14

0.15 (0.71%)

, RHHBY

Roche

$0.00

(0.00%)

19:01
06/20/19
06/20
19:01
06/20/19
19:01
Hot Stocks
Exelixis informed by Genentech that IMspire170 did not meet primary endpoint »

In a regulatory 8-k…

EXEL

Exelixis

$21.14

0.15 (0.71%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Nov

INVH

Invitation Homes

$27.68

-0.07 (-0.25%)

18:55
06/20/19
06/20
18:55
06/20/19
18:55
Syndicate
Invitation Homes 37.5M share Spot Secondary priced at ~$26.67 »

The deal priced for $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

MDB

MongoDB

$173.76

-0.33 (-0.19%)

18:44
06/20/19
06/20
18:44
06/20/19
18:44
Hot Stocks
MongoDB CEO: Every company is becoming a software company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

VRML

Vermillion

$0.89

-0.1575 (-15.00%)

18:37
06/20/19
06/20
18:37
06/20/19
18:37
Hot Stocks
Vermillion adds two contracted agreements for OVA1 cancer risk test »

Vermillion has further…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$133.66

2.97 (2.27%)

18:34
06/20/19
06/20
18:34
06/20/19
18:34
Hot Stocks
Caterpillar CEO: We take a long-term view »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$247.78

-2.47 (-0.99%)

18:22
06/20/19
06/20
18:22
06/20/19
18:22
Periodicals
Breaking Periodicals news story on UnitedHealth »

UnitedHealth said to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 18

    Jul

BKS

Barnes & Noble

$6.71

0.055 (0.83%)

18:20
06/20/19
06/20
18:20
06/20/19
18:20
Downgrade
Barnes & Noble rating change at Gabelli »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$555.39

-0.78 (-0.14%)

18:11
06/20/19
06/20
18:11
06/20/19
18:11
Hot Stocks
CoStar Group acquires Off Campus Partners »

CoStar Group has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BDX

Becton Dickinson

$245.32

7.2 (3.02%)

17:55
06/20/19
06/20
17:55
06/20/19
17:55
Hot Stocks
Becton Dickinson backs safety of its Lutonix drug-coated balloons in SFA »

BD issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CPF

Central Pacific

$28.49

-0.13 (-0.45%)

17:41
06/20/19
06/20
17:41
06/20/19
17:41
Hot Stocks
Central Pacific authorizes buyback of up to $30M in common stock »

Central Pacific announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

AEL

American Equity

$27.51

0.3 (1.10%)

17:33
06/20/19
06/20
17:33
06/20/19
17:33
Hot Stocks
American Equity director Debra Richardson sells almost $2.2M in company shares »

American Equity director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:28
06/20/19
06/20
17:28
06/20/19
17:28
Earnings
Sealed Air backs FY19 adjusted EPS view $2.65-$2.75, consensus $2.73 »

Sealed Air continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:27
06/20/19
06/20
17:27
06/20/19
17:27
Hot Stocks
Sealed Air names James Sullivan as new CFO, effective June 24 »

Sealed Air announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJRD

Aerojet Rocketdyne

$43.01

1.49 (3.59%)

17:27
06/20/19
06/20
17:27
06/20/19
17:27
Hot Stocks
Aerojet Rocketdyne subsidiary awarded $140.18M missile defense modification »

Coleman Aerospace, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:25
06/20/19
06/20
17:25
06/20/19
17:25
Hot Stocks
Sealed Air terminates CFO William Stiehl for cause, effective immediately »

Sealed Air announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBU

Brookfield Business Partners

$41.25

1.28 (3.20%)

, BAM

Brookfield

$48.38

0.29 (0.60%)

17:15
06/20/19
06/20
17:15
06/20/19
17:15
Syndicate
Brookfield Business Partners announces $795M equity offering »

Brookfield Business…

BBU

Brookfield Business Partners

$41.25

1.28 (3.20%)

BAM

Brookfield

$48.38

0.29 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

AXLA

Axcella

$10.39

0.27 (2.67%)

17:13
06/20/19
06/20
17:13
06/20/19
17:13
Earnings
Axcella reports Q1 EPS ($2.43), consensus (49c) »

Q1 operating expenses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LKSD

LSC Communications

$5.83

0.07 (1.22%)

17:11
06/20/19
06/20
17:11
06/20/19
17:11
Hot Stocks
LSC comments on DOJ action regarding proposed transaction with Quad »

LSC Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUAD

Quad/Graphics

$9.75

0.09 (0.93%)

, LKSD

LSC Communications

$5.83

0.07 (1.22%)

17:10
06/20/19
06/20
17:10
06/20/19
17:10
Hot Stocks
Quad/Graphics intends to defend proposed LSC Communications acquisition »

Quad/Graphics (QUAD)…

QUAD

Quad/Graphics

$9.75

0.09 (0.93%)

LKSD

LSC Communications

$5.83

0.07 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFM

Sprouts Farmers Market

$19.52

0.14 (0.72%)

17:04
06/20/19
06/20
17:04
06/20/19
17:04
Hot Stocks
Sprouts Farmers Market interim co-CEO/CFO Brad Lukow resigns »

Sprouts Farmers Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NAKD

Naked Brand Group

$0.27

0.0025 (0.93%)

17:03
06/20/19
06/20
17:03
06/20/19
17:03
Syndicate
Breaking Syndicate news story on Naked Brand Group »

Naked Brand Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.85

0.22 (1.07%)

16:57
06/20/19
06/20
16:57
06/20/19
16:57
Hot Stocks
HP Inc. General Counsel sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

CPT

Camden Property

$107.61

0.57 (0.53%)

16:54
06/20/19
06/20
16:54
06/20/19
16:54
Hot Stocks
Camden Property COO sells 16.2K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.